In the past week, RIGL stock has gone down by -14.38%, with a monthly gain of 50.00% and a quarterly surge of 80.23%. The volatility ratio for the week is 6.12%, and the volatility levels for the last 30 days are 9.72% for Rigel Pharmaceuticals The simple moving average for the last 20 days is -10.35% for RIGL’s stock, with a simple moving average of 70.11% for the last 200 days.
Is It Worth Investing in Rigel Pharmaceuticals (NASDAQ: RIGL) Right Now?
Rigel Pharmaceuticals (NASDAQ: RIGL) has a higher price-to-earnings ratio of 106.93x compared to its average ratio, The 36-month beta value for RIGL is at 1.23. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 4 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for RIGL is 17.27M, and currently, shorts hold a 2.68% of that float. The average trading volume for RIGL on December 10, 2024 was 205.83K shares.
RIGL) stock’s latest price update
The stock of Rigel Pharmaceuticals (NASDAQ: RIGL) has decreased by -9.00 when compared to last closing price of 25.45.Despite this, the company has seen a loss of -14.38% in its stock price over the last five trading days. prnewswire.com reported 2024-12-09 that R289 was generally well tolerated and demonstrated signs of preliminary clinical activity in elderly heavily pretreated LR-MDS patients RBC-TI/HI-E responses occurred in 40% of evaluable TD patients receiving R289 doses ≥500 mg QD SOUTH SAN FRANCISCO, Calif., Dec. 9, 2024 /PRNewswire/ — Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced initial data from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selective dual inhibitor of IRAK1 and IRAK4, in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (LR-MDS).
Analysts’ Opinion of RIGL
Many brokerage firms have already submitted their reports for RIGL stocks, with Piper Sandler repeating the rating for RIGL by listing it as a “Neutral.” The predicted price for RIGL in the upcoming period, according to Piper Sandler is $2 based on the research report published on April 03, 2023 of the previous year 2023.
Piper Sandler gave a rating of “Neutral” to RIGL, setting the target price at $1 in the report published on June 08th of the previous year.
RIGL Trading at 18.64% from the 50-Day Moving Average
After a stumble in the market that brought RIGL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.33% of loss for the given period.
Volatility was left at 9.72%, however, over the last 30 days, the volatility rate increased by 6.12%, as shares surge +4.94% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +41.05% upper at present.
During the last 5 trading sessions, RIGL fell by -14.38%, which changed the moving average for the period of 200-days by +75.45% in comparison to the 20-day moving average, which settled at $25.83. In addition, Rigel Pharmaceuticals saw 59.72% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RIGL starting from Santos David A, who sale 8,918 shares at the price of $1.14 back on Feb 05 ’24. After this action, Santos David A now owns 349,093 shares of Rigel Pharmaceuticals, valued at $10,167 using the latest closing price.
Santos David A, the EVP, Chief Commercial Officer of Rigel Pharmaceuticals, sale 5,601 shares at $1.13 during a trade that took place back on Feb 02 ’24, which means that Santos David A is holding 358,011 shares at $6,329 based on the most recent closing price.
Stock Fundamentals for RIGL
Current profitability levels for the company are sitting at:
- 0.06 for the present operating margin
- 0.89 for the gross margin
The net margin for Rigel Pharmaceuticals stands at 0.02. The total capital return value is set at 0.11.
Based on Rigel Pharmaceuticals (RIGL), the company’s capital structure generated 1.32 points at debt to capital in total, while cash flow to debt ratio is standing at 0.18. The debt to equity ratio resting at -4.08. The interest coverage ratio of the stock is 1.21.
Currently, EBITDA for the company is -16.98 million with net debt to EBITDA at 0.65. When we switch over and look at the enterprise to sales, we see a ratio of 2.64. The receivables turnover for the company is 5.15for trailing twelve months and the total asset turnover is 1.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.96.
Conclusion
In conclusion, Rigel Pharmaceuticals (RIGL) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
